PT1354888E - Derivados de glucopiranosiloxipirazole e sua utilização em medicamentos - Google Patents

Derivados de glucopiranosiloxipirazole e sua utilização em medicamentos Download PDF

Info

Publication number
PT1354888E
PT1354888E PT01994995T PT01994995T PT1354888E PT 1354888 E PT1354888 E PT 1354888E PT 01994995 T PT01994995 T PT 01994995T PT 01994995 T PT01994995 T PT 01994995T PT 1354888 E PT1354888 E PT 1354888E
Authority
PT
Portugal
Prior art keywords
medicines
glucopyranosyloxypyrazole derivatives
glucopyranosyloxypyrazole
derivatives
Prior art date
Application number
PT01994995T
Other languages
English (en)
Portuguese (pt)
Inventor
Masayuki Isaji
Toshihiro Nishimura
Nobuhiko Fushimi
Hideki Fujikura
Takeshi Nakabayashi
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18867638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1354888(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of PT1354888E publication Critical patent/PT1354888E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT01994995T 2000-12-28 2001-12-25 Derivados de glucopiranosiloxipirazole e sua utilização em medicamentos PT1354888E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000403534 2000-12-28

Publications (1)

Publication Number Publication Date
PT1354888E true PT1354888E (pt) 2009-07-27

Family

ID=18867638

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01994995T PT1354888E (pt) 2000-12-28 2001-12-25 Derivados de glucopiranosiloxipirazole e sua utilização em medicamentos

Country Status (30)

Country Link
US (5) US7084123B2 (enExample)
EP (1) EP1354888B1 (enExample)
JP (2) JP4035052B2 (enExample)
KR (1) KR100701437B1 (enExample)
CN (1) CN1238363C (enExample)
AR (1) AR032065A1 (enExample)
AT (1) ATE431830T1 (enExample)
AU (1) AU2002225356B2 (enExample)
BR (1) BRPI0116607B8 (enExample)
CA (1) CA2432145C (enExample)
CY (1) CY1109309T1 (enExample)
CZ (1) CZ305971B6 (enExample)
DE (1) DE60138768D1 (enExample)
DK (1) DK1354888T3 (enExample)
ES (1) ES2326158T3 (enExample)
HU (1) HU228915B1 (enExample)
IL (2) IL156678A0 (enExample)
MX (1) MXPA03005923A (enExample)
MY (1) MY136581A (enExample)
NO (1) NO326410B1 (enExample)
NZ (1) NZ526715A (enExample)
PE (1) PE20020722A1 (enExample)
PL (1) PL209375B1 (enExample)
PT (1) PT1354888E (enExample)
RU (1) RU2317302C2 (enExample)
SI (1) SI1354888T1 (enExample)
SK (1) SK287786B6 (enExample)
TW (1) TWI231298B (enExample)
WO (1) WO2002053573A1 (enExample)
ZA (1) ZA200304905B (enExample)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
EP1338603B1 (en) 2000-11-02 2010-01-20 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
EP1344780A4 (en) * 2000-11-30 2004-01-28 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
DE60138768D1 (de) 2000-12-28 2009-07-02 Kissei Pharmaceutical Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
CA2438593C (en) 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
EP1364958B1 (en) 2001-02-27 2010-09-08 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
CN100577175C (zh) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
CN100384430C (zh) 2001-04-04 2008-04-30 奥索-麦克尼尔药品公司 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗
CA2672001A1 (en) 2001-04-27 2002-11-07 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US7956041B2 (en) * 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US6933292B2 (en) * 2002-07-30 2005-08-23 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
ATE469161T1 (de) * 2002-08-08 2010-06-15 Kissei Pharmaceutical Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
CN100351263C (zh) * 2002-08-08 2007-11-28 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
KR100588457B1 (ko) * 2002-08-09 2006-06-12 다이쇼 세이야꾸 가부시끼가이샤 아릴 5-티오-β-Ｄ-글루코피라노시드 유도체 및 이를함유하는 당뇨병 치료약
CN100413878C (zh) * 2002-08-23 2008-08-27 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
WO2004019958A1 (ja) * 2002-08-27 2004-03-11 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
TW200406199A (en) * 2002-08-30 2004-05-01 Mitsubishi Pharma Corp Preventive and/or therapeutic agent for heart failure
AU2003272903A1 (en) * 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
EP1568380A4 (en) * 2002-12-04 2009-10-21 Kissei Pharmaceutical PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA
EP1577317A4 (en) * 2002-12-25 2007-05-09 Kissei Pharmaceutical NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, MEDICINAL COMPOSITIONS COMPRISING SAID DERIVATIVES AND MEDICAL USE OF SAID DERIVATIVES
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
ATE541854T1 (de) * 2003-06-20 2012-02-15 Kissei Pharmaceutical Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
TWI385177B (zh) 2003-08-01 2013-02-11 Mitsubishi Tanabe Pharma Corp 吡喃葡萄糖基衍生物及其製造方法
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
CA2539032A1 (en) * 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2572793C (en) * 2004-07-21 2015-11-03 Kissei Pharmaceutical Co., Ltd. Progression inhibitor for disease attributed to abnormal accumulation of liver fat
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
TR201906416T4 (tr) 2004-07-27 2019-05-21 Gilead Sciences Inc Hiv inhibitörü bileşiklerin fosfonat analogları.
WO2006034435A2 (en) * 2004-09-21 2006-03-30 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
MY147375A (en) * 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
CA2600372C (en) * 2005-03-17 2013-04-02 Kissei Pharmaceutical Co., Ltd. Process for production of glucopyranosyloxypyrazole derivative
KR20080036112A (ko) * 2005-07-22 2008-04-24 베링거 인겔하임 인터내셔날 게엠베하 피라졸-ｏ-글리코시드 유도체의 제조 방법 및 당해 방법의신규한 중간체
UY29694A1 (es) * 2005-07-28 2007-02-28 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
MY145464A (en) * 2005-08-31 2012-02-15 Hoffmann La Roche Pyrazolone derivatives as 11-beta hsd1 inhibitors
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
CN100384416C (zh) * 2006-03-20 2008-04-30 杨军 一种用于治疗心血管疾病的药物组合物
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
ES2397664T3 (es) 2006-12-04 2013-03-08 Janssen Pharmaceutica, N.V. Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
KR20090097184A (ko) 2006-12-06 2009-09-15 스미스클라인 비참 코포레이션 비시클릭 화합물 및 항당뇨병제로서의 용도
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CA2699285C (en) * 2007-09-10 2016-12-13 Ahmed F. Abdel-Magid Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt)
ES2548578T3 (es) * 2007-12-27 2015-10-19 Kissei Pharmaceutical Co., Ltd. Monosebacato de un derivado de pirazol
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
BRPI0915878A2 (pt) * 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
KR101338540B1 (ko) * 2008-08-28 2013-12-06 화이자 인코포레이티드 다이옥사-바이사이클로[3.2.1]옥테인-2,3,4-트라이올 유도체
US20100113604A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113580A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010045417A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010045416A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010045529A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20100167989A1 (en) * 2008-10-23 2010-07-01 Auspex Pharmaceuticals, Inc. Isopropoxyphenylmethyl inhibitors of sglt2
AP2011005794A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof.
EP2416797A4 (en) * 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
EP2424543A4 (en) * 2009-04-30 2012-10-17 Glaxosmithkline Llc CHEMICAL PROCESS
US20100331419A1 (en) * 2009-06-25 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331420A1 (en) * 2009-06-26 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331999A1 (en) * 2009-06-29 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
HRP20130561T1 (en) 2009-07-10 2013-07-31 Janssen Pharmaceutica Nv CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
WO2011009115A2 (en) * 2009-07-17 2011-01-20 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2011041632A2 (en) * 2009-10-01 2011-04-07 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
KR101730920B1 (ko) 2009-10-14 2017-04-27 얀센 파마슈티카 엔.브이. Ｓｇｌｔ2의 억제제로서 유용한 화합물의 제조 방법
KR101426180B1 (ko) 2009-11-02 2014-07-31 화이자 인코포레이티드 디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
MX2012008961A (es) * 2010-02-03 2013-04-29 Meh Associates Inc Fluorometanos multiples sustituidos como isosteros selectivos y bioactivos.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20140088027A1 (en) 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
HRP20161231T1 (hr) 2010-05-11 2016-11-04 Janssen Pharmaceutica N.V. Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore
RU2016125229A (ru) * 2010-07-09 2018-12-04 БиЭйчВи ФАРМА, ИНК. Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR101702702B1 (ko) * 2011-01-10 2017-02-03 무하메드 마제에드 칼레빈 ａ의 항-비만 가능성
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CA2837627A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
RU2517091C2 (ru) * 2012-02-20 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации) Средство, обладающее мочегонным действием
RU2500407C2 (ru) * 2012-02-20 2013-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Средство, обладающее мочегонным действием
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
WO2014161836A1 (en) 2013-04-04 2014-10-09 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
AU2014364999B2 (en) 2013-12-17 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in feline animals
BR112016014716B1 (pt) 2013-12-26 2022-10-04 Posco Aparelho e método de fundição e laminagem contínuas
CN105960242A (zh) 2014-01-23 2016-09-21 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
US10688116B2 (en) 2014-04-01 2020-06-23 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
KR102539788B1 (ko) 2014-09-25 2023-06-07 베링거잉겔하임베트메디카게엠베하 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
KR200484486Y1 (ko) * 2016-05-09 2017-09-12 연세대학교 원주산학협력단 시료채취장치
MX2019004549A (es) 2016-10-19 2019-06-12 Boehringer Ingelheim Int Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
BR112020010831A2 (pt) 2017-11-30 2020-11-10 Idorsia Pharmaceuticals Ltd composição farmacêutica, aprocitentan, e, método
WO2019193572A1 (en) * 2018-04-05 2019-10-10 Glenmark Pharmaceuticals Limited An improved process for the preparation remogliflozin etabonate or pharmaceutically acceptable salt, solvate, hydrate thereof
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
KR102812426B1 (ko) 2018-10-29 2025-05-26 베링거 인겔하임 인터내셔날 게엠베하 피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
AU2020394498A1 (en) 2019-11-28 2022-06-09 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
MX2022010090A (es) 2020-02-17 2022-09-02 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
MX2024001184A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
IL314031A (en) 2021-12-30 2024-09-01 Newamsterdam Pharma B V Obicetrapib and sglt2 inhibitor combination
CA3256728A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING SGLT-2 INHIBITORS
TW202500160A (zh) 2023-03-06 2025-01-01 德商百靈佳殷格翰維美迪加股份有限公司 用於遞送特別是包含一或多種ｓｇｌｔ—２抑制劑之液體醫藥組合物之系統及方法
AR132497A1 (es) 2023-04-24 2025-07-02 Newamsterdam Pharma B V Combinación de obicetrapib amorfo e inhibidor de sglt2
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2024254352A1 (en) * 2023-06-06 2024-12-12 Vogenx Sglt1 inhibitor and incretin combinations for treating metabolic disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659655B1 (fr) * 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5264451A (en) * 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
CN1145635C (zh) 1999-08-31 2004-04-14 橘生药品工业株式会社 吡喃葡糖氧基吡唑衍生物、含该衍生物的药物组合物及其制备中的中间体
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
EP1338603B1 (en) * 2000-11-02 2010-01-20 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
DE60138768D1 (de) 2000-12-28 2009-07-02 Kissei Pharmaceutical Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
CA2438593C (en) * 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
JP2003072176A (ja) * 2001-09-03 2003-03-12 Olympus Optical Co Ltd 画像記録装置
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US6731109B2 (en) * 2002-07-12 2004-05-04 Wabash Technologies, Inc. Magnetic position sensor having a stepped magnet interface

Also Published As

Publication number Publication date
IL156678A0 (en) 2004-01-04
SK287786B6 (sk) 2011-09-05
ES2326158T3 (es) 2009-10-02
AU2002225356B2 (en) 2008-03-06
EP1354888A1 (en) 2003-10-22
US20090093419A1 (en) 2009-04-09
KR20030063482A (ko) 2003-07-28
MXPA03005923A (es) 2004-01-26
JP4758964B2 (ja) 2011-08-31
PL209375B1 (pl) 2011-08-31
CY1109309T1 (el) 2014-07-02
US20060035847A1 (en) 2006-02-16
CZ305971B6 (cs) 2016-06-01
CA2432145A1 (en) 2002-07-11
JPWO2002053573A1 (ja) 2004-05-13
EP1354888A4 (en) 2004-01-28
TWI231298B (en) 2005-04-21
US20040063646A1 (en) 2004-04-01
US20060094667A1 (en) 2006-05-04
NZ526715A (en) 2005-02-25
MY136581A (en) 2008-10-31
WO2002053573A1 (en) 2002-07-11
ZA200304905B (en) 2004-06-24
NO326410B1 (no) 2008-12-01
JP2008007519A (ja) 2008-01-17
US7465713B2 (en) 2008-12-16
US7084123B2 (en) 2006-08-01
US7989424B2 (en) 2011-08-02
NO20032909L (no) 2003-08-27
DE60138768D1 (de) 2009-07-02
AR032065A1 (es) 2003-10-22
DK1354888T3 (da) 2009-09-21
PE20020722A1 (es) 2002-09-30
US20060025352A1 (en) 2006-02-02
BR0116607A (pt) 2004-04-20
PL365284A1 (en) 2004-12-27
CN1492873A (zh) 2004-04-28
HK1062914A1 (en) 2004-12-03
US7393838B2 (en) 2008-07-01
BRPI0116607B8 (pt) 2021-05-25
SI1354888T1 (sl) 2009-10-31
HUP0302550A3 (en) 2009-08-28
CN1238363C (zh) 2006-01-25
IL156678A (en) 2010-03-28
CZ20031753A3 (cs) 2003-10-15
BRPI0116607B1 (pt) 2016-12-27
KR100701437B1 (ko) 2007-03-30
SK8092003A3 (en) 2004-01-08
RU2317302C2 (ru) 2008-02-20
HUP0302550A2 (hu) 2003-11-28
EP1354888B1 (en) 2009-05-20
US7429568B2 (en) 2008-09-30
CA2432145C (en) 2010-07-13
ATE431830T1 (de) 2009-06-15
JP4035052B2 (ja) 2008-01-16
HU228915B1 (en) 2013-06-28
NO20032909D0 (no) 2003-06-24

Similar Documents

Publication Publication Date Title
IL156678A0 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
PT1296974E (pt) Derivados 2-cianopirrolidina e sua utilização como medicamentos
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
HUP0300746A3 (en) Proline derivatives and use thereof as drugs
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
HUP0302997A3 (en) Phenylalanine derivatives with alpha4-integrin effect, pharmaceutical compositions containing them and their use
AU9667901A (en) Mycoattractants and mycopesticides
PL362177A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
IL151919A0 (en) Imidazopyridine derivatives and triazolpyrimidine derivatives
GB0101035D0 (en) Formulation and use thereof
HUP0301230A3 (en) Phenylpyridazine derivatives and drugs containing the same
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
AU2002343103A1 (en) Aminoalkylimidazole derivatives and their use in medicine
GB0023323D0 (en) Arylhydantoin derivatives and uses thereof
GB2368612B (en) Improvements in and relating to karabiners
GB0022360D0 (en) Improvemnts in and related to sensors
PL363048A1 (en) Azabicyclic derivatives and their therapeutic use
AU2003218261A8 (en) Improvements in pharmaceutical discovery and development
HUP0203383A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
EP1154783A4 (en) RELAXIN-CONTAINING MEDICAMENTS AND ITS USE
IL134240A0 (en) Inositol derivatives and their pharmaceutical use